MedTrace Logo

Comparison of Image Quality Between "Double Low Dose" Liver CT and Standard Liver CT

NCT05790590 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2023-06-05

No results posted yet for this study

Summary

In patients with malignancies, contrast-enhanced abdominal CT (hereafter abdominal CT) plays an important role in detecting carcinoma recurrence and assessing treatment response. In this study, we aim to investigate whether such a "double low" dose CT is feasible in patients with liver metastases of colorectal cancer using a vendor-agnostic artificial intelligence-based noise reduction and contrast enhancement software.

Conditions

Interventions

DIAGNOSTIC_TEST

Double low dose CT

Simultaneous reduction of both radiation dose and contrast media dose

DIAGNOSTIC_TEST

Standard dose CT

CT with standard radiation dose and contrast media dose

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jeong Min Lee, MD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05790590 on ClinicalTrials.gov